Stopping Pneumonia Antibiotherapy Regimen Early
Key facts
- Who runs it
- University Hospital, Montpellier
- Where
- France10 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 1,100 people, planned
- Started
- 1 Sept 2024
- Expected to end
- 1 Sept 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Quick response: Amoxicillin for 3 days
- Delayed response: Amoxicillin for 5 days
- Quick response: Amoxicillin for 5 days
- Delayed response: Amoxicillin for 7 days
- Record updated
- 20 May 2024
Who can take part
- Age
- 3 months to 59 months
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Child with a diagnosis of community-acquired alveolar pneumonia defined as an association of 3 major criteria + at least 3/5 minor criteria:; Major criteria: Fever (> 38°C), Polypnea and Chest x-ray; Minor criteria: Localized crackles, C-Reactive Protein (CRP) > 80mg/L, Alteration of general condition, Cough and Pulmonary condensation syndrome
- Child with an episode that began less than 7 days before inclusion, in the community
- Absence of hospitalization criteria
Who cannot take part
- Pre-existing underlying pathology: acquired or hereditary immune deficiencies, cardiac pathologies, chronic respiratory failure or pulmonary malformations, neurological or muscular diseases at risk of respiratory decompensation, serious chronic kidney diseases and nephrotic syndromes, sickle cell anemia, diabetes, chronic liver diseases, oncological pathologies and hematological, organ and hematopoietic stem cell transplants, inflammatory and/or autoimmune diseases receiving immunosuppressive treatment, people infected with HIV, obese people with a body mass index (BMI) ≥ the 97th percentile
- Antibiotic therapy within 48 hours before inclusion
- Anti-inflammatory therapy within 48 hours before inclusion
- Patient hospitalized within 15 days before inclusion
- Allergy or contraindication to penicillin
- History of more than 2 bacterial pneumonias per year
- Associated infection requiring more than 3 days of antibiotics
- Failure to obtain informed consent by the legal representative(s)
- Asthma with basic treatment
- Wheezing during the episode
- Presence of pleural effusion on radiography
- Presence of toxin signs
- Patient whose legal representatives are unable to read/write french language
- Patient not affiliated with or not benefiting from a national health insurance scheme
- Patient participating in another interventional research involving human person
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The hypothesis for this trial is that an antibiotic strategy for the management of non-severe community-acquired alveolar pneumonia in children aged 3 to 59 months, including amoxicillin 80-100 mg/kg/day for at least 3 days in case of rapid response and 5 days in case of delayed response, would not be inferior to current French recommendations (antibiotic therapy for 5 days in case of rapid response and 7 days in case of delayed response) in terms of treatment of failure rate at 7 days.
The 2 groups in the trial
- Short armTreatment being tested
Antibiotic therapy for 3 to 5 days depending on response
Treatment: Quick response: Amoxicillin for 3 days and Delayed response: Amoxicillin for 5 days
- Long armExisting treatment, for comparison
Antibiotic therapy for 5 to 7 days depending on response
Treatment: Quick response: Amoxicillin for 5 days and Delayed response: Amoxicillin for 7 days
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Evaluation of a Therapeutic Strategy to Reduce the Duration of Antibiotic Therapy for Community-acquired Alveolar Pneumonia in Children: a Randomized Controlled Non-inferiority Trial
- Record updated
- 20 May 2024